PhaseBio

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PhaseBio and other ETFs, options, and stocks.

About PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. 

CEO
Jonathan P. Mow
CEOJonathan P. Mow
Employees
60
Employees60
Headquarters
Malvern, Pennsylvania
HeadquartersMalvern, Pennsylvania
Founded
2002
Founded2002
Employees
60
Employees60

PHAS Key Statistics

Market cap
8.80M
Market cap8.80M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
1.37M
Average volume1.37M
High today
$0.227
High today$0.227
Low today
$0.17
Low today$0.17
Open price
$0.1815
Open price$0.1815
Volume
2.20M
Volume2.20M
52 Week high
$4.10
52 Week high$4.10
52 Week low
$0.17
52 Week low$0.17

PHAS Earnings

-$0.90
-$0.60
-$0.30
-$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Nov 9, Pre-Market
ActualExpected Nov 9, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC.